m2-5 quiz Flashcards
Which of the following statements is right?
A. Pharming is the breeding of transgenic disease models.
B. Pharming has nothing to do with genetic manipulation.
C. Pharming refers to the production of recombinant proteins in livestock.
D. The most efficient livestock for pharming is cattle.
E. Pharming refers to the production of drug-free meat.
C. Pharming refers to the production of recombinant proteins in livestock.
Which of the following is NOT an early sign of brain ischemia on computed tomography (CT)?
A. Hyperdense artery sign
B. Dural tail sign
C. Insular ribbon sign
D. Effacement of the sulci
E. Loss of the lentiform nucleus
B. Dural tail sign
Which of the following statements is TRUE?
A. The main role of MR angiography (MRA) is for visualizing the ischemic penumbra
B. Intravenous thrombolysis is indicated up to 9 hours following stroke symptom onset in Europe
C. The abundance of collateral flow has a generally detrimental effect on stroke outcome
D. “Time shift analysis” measures perfusion by tracking a bolus of intravenously injected Gadolinium
E. Longer thrombi are associated with less successful recanalization after thrombolysis
E. Longer thrombi are associated with less successful recanalization after thrombolysis
The primary outcome of a First-in-Human study is always:
A. Safety and tolerability
B. Feasability
C. Pharamcodynamics
D. Therapeutic effect
A. Safety and tolerability
Which of the following answers is correct?
A. The NOAEL is defined as the highest dose at which no clinical and/or biological relevant adverse effect is observed in preclinical toxicology studies
B. The NOAEL is defined as the lowest dose at which at least one clinical and/or biological relevant adverse effect is observed in preclinical toxicology studies
A. The NOAEL is defined as the highest dose at which no clinical and/or biological relevant adverse effect is observed in preclinical toxicology studies
Which of the following statements is correct?
A. The NOAEL is defined as the highest dose at which no clinical and/or biological relevant adverse effect is observed in preclinical toxicology studies.
B. The NOAEL is defined as the lowest dose at which at least one clinical and/or biological relevant adverse effect is observed in preclinical toxicology studies.
A. The NOAEL is defined as the highest dose at which no clinical and/or biological relevant adverse effect is observed in preclinical toxicology studies.
Which of the following imaging patterns has been shown to reliably identify patients whose symptoms began no more than 4.5 hours prior to imaging?
A. Positive lesion on DWI and negative lesion on FLAIR
B. Positive lesion on DWI and positive lesion on perfusion imaging
C. Negative lesion on DWI and positive lesion on FLAIR
D. Negative lesion on DWI and positive lesion on perfusion imaging
E. Positive lesion on DWI and vessel occlusion on MRA
A. Positive lesion on DWI and negative lesion on FLAIR
What are the legal preconditions for the conduct of a clinical study?
(more than one answer is correct)
A. IRB approval
B. Insurance Certificate
C. Data protection approval
D. Youth welfare office approval
E. Study bank account
A. IRB approval
B. Insurance Certificate
C. Data protection approval
The primary outcome of a First-in-Human study is always:
A. Safety and tolerability
B. Feasibility
C. Pharmacodynamics
D. Therapeutic effect
A. Safety and tolerability
To analyse a cell-type specific knockout you need
(more than one answer is correct)
A. a transgenic mouse strain harboring a cell type-specific Cre transgene
B. a transgenic mouse strain harboring a “floxed” allele
C. a facility for zygote injection
D. a facility for embryonic stem cell culture
E. a means to detect your gene product of choice
A. a transgenic mouse strain harboring a cell type-specific Cre transgene
B. a transgenic mouse strain harboring a “floxed” allele
E. a means to detect your gene product of choice
Which brain function is dominated most by one hemisphere?
A. Hearing
B. Smelling
C. Language
D. Memory
E. Vision
C. Language
Which study(ies) belong(s) to Phase I? (more than one answer might be correct)
A. Bioequivalence
B. First in Human
C. Pharmacokinetics in renal impairment
D. Proof of concept
E. Pharmacokinetic drug interaction
A. Bioequivalence
B. First in Human
C. Pharmacokinetics in renal impairment
E. Pharmacokinetic drug interaction
Embryonic stem cells are
A. forming the trophoectoderm of an embryo
B. maintained in culture in the absence of LIF
C. derived from the trophoectoderm of an embryo
D. needed for pronucleus injection
E. derived from the inner cell mass of a blastocyst
E. derived from the inner cell mass of a blastocyst
